The finding that the MAPKs inhibitors very effectively inhibited several cytokines in CD4+ T cells costimulated through CD28 and ICOS, prompted us to investigate whether these selective MAPKs inhibitors may be active in an animal model of allergic asthma. Here, CD4 is linked to allergic asthma.